Pharmacokinetic analysis of cfapsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain

Therapeutic Drug Monitoring

Volumn 31, Issue 4, 2009, Pages 502-510

  Babbar, Sunita ^a   Marier, Jean Francois ^b   Mouksassi, Mohamad Samer ^b   Beliveau, Martin ^b   Vanhove, Geertrui F ^a   Chanda, Sanjay ^c   Bley, Keith ^a  

^a NeurogesX Inc   (United States)

^b PHARSIGHT CORPORATION   (Canada)

^c PFIZER INC   (United States)

Author keywords

Capsaicin; Painful neuropathy; Patch; Pharmacokinetics; Topical

Indexed keywords

CAPSAICIN; LIDOCAINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOOT; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; PARAMETER; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; TRUNK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRADERMAL DRUG ADMINISTRATION; KINETICS; METABOLISM; PAIN; PAIN ASSESSMENT; PEPPER; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; CAPSAICIN; CAPSICUM; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; MALE; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 68449096248     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181a8b200     Document Type: Article

References (21)

1. Pingle SC, Matta JA, Ahern GP. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;179:155-171.
2. Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des. 2008;14:32-41.
3. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159-212.
4. Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs. 2004;13:1445-1456.
5. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328:991.
6. Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg. 1998;86:579-583.
7. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106-1112.
8. Simpson DM, Brown S, Tobias J, et al. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305-2313.
9. Chanda S, Bashir M, Babbar S, et al. In vitro hepatic and skin metabolism of capsaicin. Drug Metab Dispos. 2008;36:670-675.
10. Beaudry F, Vachon P. Quantitative determination of capsaicin, a transient receptor potential channel vanilloid 1 agonist, by liquid chromatography quadrupole ion trap mass spectrometry: evaluation of in vitro metabolic stability. Biomed Chromatogr. 2009;23:204-211.
11. Parrish M. Liquid chromatographic method for determining capsaicinoids in capsicums and their extractives: collaborative study. J AOAC Int. 1996;79:738-745.
12. European Commission, Scientific Committee on Food. SCF/CS/FLAV/FLAVOUR/8 ADD1 Final. February 28, 2002. Available at: http://ec.europa.eu/food/fs/sc/scf/ out120-en.pdf. Accessed March 19, 2009.
13. Fang JY, Wu PC, Huang YB, et al. In vivo percutaneous absorption of capsaicin, nonivamide and sodium nonivamide acetate from ointment bases: pharmacokinetics analysis in rabbits. Int J Pharm. 1996;128:169-177.
14. Fang JY, Wu PC, Huang YB, et al. In vivo permeation study of capsaicin and its synthetic derivatives from ointment bases using various skin types. Int J Pharm. 1995;126:119-128.
15. Kawada T, Suzuki T, Takahashi M, et al. Gastrointestinal absorption and metabolism of capsaicin and dihydrocapsaicin in rats. Toxicol Appl Pharmacol. 1984;72:449-456.
16. Lejeune MP, Kovacs EM, Westerterp-Plantenga MS, et al. Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. Br J Nutr. 2003;90:651-659.
17. Chaiyasit K, Khovidhunkit W, Wittayalertpanya S. Pharmacokinetics and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J Med Assoc Thai. 2009;92:108-113.
18. Chanda S, Mould A, Esmail A, et al. Toxicity studies with pure trans-capsaicin delivered to dogs via intravenous administration. Regul Toxicol Pharmacol. 2005;43:66-75.
19. Brunton L, Lazo J, Parker K. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill Professional; 2005.
20. Holbrook KA, Odland GF. Regional differences in the thickness (cell layers) of the human stratum corneum: an ultrastructural analysis. J Invest Dermatol. 1974;62:415-422.
21. Walpole CS, Wrigglesworth R, Bevan S, et al. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region." J Med Chem. 1993;36:2362-2372.